Default Theme
Increase size
Reset to Default
Decrease size
AIIMS NEW
अखिल भारतीय आयुर्विज्ञान संस्थान, नई दिल्ली
All India Institute Of Medical Sciences, New Delhi

ICGGC 2020

 

Conference Agenda

The Indian Cancer Genetics and Genomics Conference-2020  

The Indian Cancer Genetics and Genomics Conference-2020 (ICGGC-2020) was organized on a hybrid-virtual platform on the 24th and 25th of November 2020. This was organised by the Department of Medical Oncology, AIIMS, New Delhi in association with the Indo-UK Genetic Education Forum, under the aegis of the Research and Education Society of medical Oncology (RESMO).

Genetics and genomics are playing an ever-increasing role in deciding the management of cancers, be it the diagnosis, prognosis, precision therapeutic management or precision prevention. The role of genomics and genetics in oncology is evolving at an extremely fast pace and it is prudent to keep abreast of it. Precision prevention, particularly identifying the high-risk families and unaffected relatives has a tremendous potential for preventing cancers and altering the natural history of the disease. With this intent in mind, this conference was planned to present the current state-of -the art management in Clinical Cancer Genetics. It was an educational event targeted to the residents training in medical, surgical, radiation oncology and gynaecological and breast surgery in different institutes all over the country.

The conference had a galaxy of esteemed faculty, including renowned clinicians and geneticists from the United kingdom, the United Sates, leading academic institutes across the length and breadth of India including AIIMS-New Delhi, Tata Memorial Hospital-Mumbai, PGIMER-Chandigarh, JIPMER-Puducherry, Cancer Institute-Adyar, Chennai.

The first day was dedicated to Hereditary breast and ovarian cancers and the speakers explained the current concepts and the state- of – the art practice. Important data from European and Indian studies were presented and discussed. Panel discussion explaining the important aspects of clinical management was organised. The second day was dedicated was Lynch syndrome, Li Fraumeni, Retinoblastoma and other miscellaneous cancers. The laboratory principles, technical details of reporting, genetic counselling etc were addressed.

The event was attended online and appreciated by more than 800 viewers all over the world. The videos of the event, both days 1 & 2 are available at the link on the institute website.

Day 1:

https://drive.google.com/file/d/1vQpvHhXdpYiTrqgoV_szWZsl1eqrj12z/view?usp=sharing  

Day 2:

https://drive.google.com/file/d/1ft2HFDx3pAUeWXKSt7nqDonAz2II1yev/view?usp=sharing

Dr. Deepam Pushpam

Name: Dr. Deepam Pushpam

Qualification: MD (Internal Medicine), DM (Medical Oncology)

Designation: Assistant Professor, Department of Medical Oncology.

Address: Room No. 245, Department of Medical Oncology 2nd Floor, Dr B.R.A-I.R.C.H, AIIMS , Ansari Nagar, New Delhi 110029.

Contact info: Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Academic career: Dr. Deepam Pushpam graduated from the Guwahati Medical College, Guwahati University and received his MD degree in Internal Medicine from AIIMS, Delhi. He did his senior resident ship in Medical oncology at the Dr. B. R. A- IRCH, AIIMS, New Delhi and completed his DM degree in Medical Oncology from AIIIMS. He was recruited as a faculty in Medical Oncology at the Dr. B R A –IRCH, AIIMS, New Delhi in 2018.

Area of Expertise: Dr. Deepam Pushpam is a member of the multidisciplinary teams at Dr. B.R.A-IRCH taking care of   pediatric solid cancer, soft tissue sarcoma, melanoma, pediatric and adult hematological malignancies and hematopoietic stem cell transplant. He routinely takes care of these patients in the OPD and wards. He has keen interest in hematopoietic stem cell transplant for congenital disorders in children, cord blood transplant, allogeneic hematopoietic stem cell transplant and haploidentical stem cell transplant. He also actively participates in clinical services for lung cancer.

Research interest: Acute lymphoblastic leukemia, chronic myeloid leukemia, rare pediatric tumors, and soft tissue sarcoma.

Awards:

  1. Geeta Mittal Award for Best Research in Oncology AIIMS, Delhi 2018.
  2. Best Thesis in Oncology ICON 2018

Membership of Professional bodies:

1.            Member: European Society for Medical Oncology, (ESMO).

2.            Member: Indian Society of Medical and Paediatric Oncology,(ISMPO)

3.            Member: Paediatric Hemato-Oncology chapter of Inadian Academy of Paediatrics (PHO-IAP)

Selected publications:

  1. Pushpam, D., Bakhshi, S. Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective. DARU J Pharm Sci (2020). doi.org/10.1007/s40199-019-00321-z
  2. Pushpam D, Bakhshi S. Paediatric chronic myeloid leukaemia: Is it really a different disease?Indian J Med Res. 2019 May;149(5):600-609. doi: 10.4103/ijmr.IJMR_331_19. Review.
  3. Pushpam D, Rajput N, Chopra A, Vishnubhatla S, Kumari M, Kumar R, Bakhshi S.Association of absolute lymphocyte count and peripheral blood lymphocyte subsets percentage with minimal residual disease at the end of induction in pediatric B cell acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2019 Apr;36(3):138-150. doi: 10.1080/08880018.2019.1594469. Epub 2019 May 3.
  4. Pushpam D, Chopra A, Sreenivas V, Kumar R, Bakhshi S.Absolute Lymphocyte Count at the End of Induction as a Surrogate Marker for Minimal Residual Disease in T-cell Acute Lymphoblastic Leukemia. Pushpam D, Chopra A, Sreenivas V, Kumar R, Bakhshi S. Indian Pediatr. 2019 May 15;56(5):381-383.
  5. Ganguly S, Pushpam D, Mian A, Chopra A, Gupta R, Bakhshi S. Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India. Clin Lymphoma Myeloma Leuk. 2020 Mar 6. pii: S2152-2650(20)30112-9. doi: 10.1016/j.clml.2020.02.015.
  6. Kancharla H, Gundu N, Pathak N, Vandidassane I, Khurana S, Pushpam D, Jain D, Kumar S, Pathy S, Mohan A, Malik PS.Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice. Curr Probl Cancer. 2020 Jan 20:100550. doi: 10.1016/j.currproblcancer.2020.100550.Review.

PhD Alumini

Alumini

S.NONAMESMONTH AND YEAR OF PASSINGPHOTO
1DR. GOTTEMUKKALA MURALIK RAJUFeb-99  
2DR. ASHUTOSH PATHAKMay-02 
3DR. PRATIBHA SHARMA Jan-10 
4DR. RASHMI  BHARDWAJSep-10 
5DR. RAKESH VERMAMar-11 
6DR. NITIN MATHURFeb-12 
7DR. SURENDER KUMAR SHARAWATMay-13 
8DR.NIVEDITA PATHAKSep-13 
9Dr. Minakshi Mann

February 2014 – July 2020

10

Dr. Anudishi Tyagi

January 2013 - February 2019
11Dr. Shivali Jasrotia August 2011 - July 2019
12

Dr. Mohsin Maqbool

February 2010 - December 2018

 

Dr. ATUL BATRA

 

 BIOGRAPHICAL DATA

 

Name: Atul Batra

Address: New Delhi, India

Telephone/Email: +91-11-29575232/ This email address is being protected from spambots. You need JavaScript enabled to view it.

Present rank: Associate Professor

Department: Medical Oncology

Faculty: Medicine

Institution: All India Institute of Medical Sciences, New Delhi

Date of Birth: 02 January 1986

 

Major clinical interests

Dr.Batra is a member of the multidisciplinary teams at Dr. B.R.A-IRCH taking care of Breast cancer, and Genitourinary cancers and routinely takes care of these patients in the OPD and wards.

 

Major research interests

  • Breast Cancer

  • Prostate Cancer

  • Renal Cell Cancer

  • Urinary Bladder Cancer

  • Germ Cell Tumor

ACADEMIC RECORD

 

Post-Secondary Education

Institution/University

 

 

 

Degree

Subject/Area

Dates

 

Maulana Azad Medical College, Delhi University

 

MBBS

General Medicine and Surgery

July 2003 to December 2008

All India Institute of Medical Sciences, New Delhi

 

MD

Internal Medicine

January 2009 to December 2011

All India Institute of Medical Sciences, New Delhi

 

Tom Baker Cancer Centre,

Calgary, Canada

DM

 

 

Fellowship

Medical Oncology

 

 

Breast cancer and Health Services Research

 

January 2013 to December 2015

 

July 2019 to June 2020

 

Continuing Education and Training

 

Institution / University

Rank or Title

Dates

 Maulana Azad Medical College, Delhi University, India  

Intern

January 2008 to December 2008

 All India Institute of Medical Sciences, New Delhi, India 

Senior Resident, Internal Medicine

January 2012 to October 2012

 All India Institute of Medical Sciences, New Delhi

Senior resident, Medical Oncology

January 2016 to November 2016

 Second University of Naples, Italy

Translational Research Unit Fellow 

 

 

April 2016

 Memorial Sloan Kettering Cancer Centre, New York, USA

nternational CML Foundation Fellow 

October 2017 to November 2017

 Tom Baker Cancer Centre, University of Calgary

Clinical and Research Fellow

July 2019 to present 

 Stanford University

Medical Statistics I-III (Certificate course) 

May 2020-May 2021

 All India Institute of Medical Sciences, new Delhi

Part-time Fellowship in Research Methodology and Evidence Based Medicine

January 2021-ongoing

 

 

Board Exams and Certifications

 

Year

Board Exam/Certificate

 

2015

European Society of Medical Oncology Exam

2017

Diplomate of National Board (Medical Oncology), India

2017

Membership of the Royal Colleges of Physicians of the United Kingdom

Speciality Certificate Exam (Medical Oncology)

2018

Membership of the Royal Colleges of Physicians of the United Kingdom Part 1 and 2

 

Medical Licensure

Year

Licensing Body

Subject/Area

2008-present

Delhi Medical Council

General

2012-present

Delhi Medical Council

Specialist: Internal Medicine

2016-present

Delhi Medical Council

Specialist: Medical Oncology

2019-2020

College of Physicians and Surgeons of Alberta

Post graduate medical trainee, Medical Oncology

 
 
ACADEMIC APPOINTMENTS
 

 University, Company or Organization 

Rank or Title

Dates

All India Institute of Medical Sciences, New Delhi, India

 

Associate Professor

July 2020 to present

All India Institute of Medical Sciences, New Delhi, India

Assistant Professor

November 2016 to June 2020

 

 

 

 
 
 
AWARDS AND DISTINCTIONS
 

Year

Description

City, Country

2021

ASCO International Innovation Grant

USA

2020

Coltman Scholar Award at San Antonio Breast Cancer Symposium 2020

San Antonio, USA

2020

ASCO Merit Award in Quality Care Symposium 2020

Chicago, USA

2020

Novartis Oncology Young Canadian Investigator Award 2020

Calgary, Canada

2020

Young Investigator Award, ESMO World GI Congress 2020

Barcelona, Spain

2020

ASCO Merit Award at Annual ASCO meeting 2020

Chicago, USA

2020

ESMO Breast 2020 Merit Award- Travel Grant

Berlin, Germany

2018

President Gold Medal for the Best Diplomate of National Board in Medical Oncology

Delhi, India

2018

European Society of Medical Oncology (ESMO) Travel Award for Preceptorship on Breast Cancer

Singapore

2018

European Society of Medical Oncology (ESMO) Travel Award for Preceptorship on Prostate Cancer

Singapore

2017

International CML preceptorship award

New York, USA

2017

Young Investigator Award at International Society of Paediatric Oncology Annual Meeting

Washington DC, USA

2016

Department of Science and Technology International Travel Award

Delhi, India

2016

Multinational Association of Supportive Care in Cancer Annual Meeting Scholarship Award

Adelaide, Australia

2016

European Society of Medical Oncology (ESMO) Translational Research Fellowship Award

Naples, Italy

2016

Gold medal (Smt. Shakuntala Jolly Award) for the Best DM student in Medical Oncology at All India Institute of Medical Sciences

Delhi, India

2016

Best Clinical research (Smt. Geeta Mittal Award) in Oncology in All India Institute of Medical Sciences

Delhi, India

2015

Young Investigator Award at International Society of Paediatric Oncology Annual Meeting

Cape town, South Africa

2015

European Society of Medical Oncology (ESMO) Asia Annual Meeting Scholarship Award

Singapore

 

2015

European Society of Medical Oncology (ESMO) Travel Award for Preceptorship on Prostate Cancer

Prague, Czech Republic

2015

Indian Council for Medical Research International Travel Award for American Society of Clinical Oncology (ASCO) Annual Meeting

Chicago, USA

2015

European Society of Medical Oncology (ESMO) Travel Award for Preceptorship on Non-small Cell Lung Cancer

Singapore

2014

Awarded first prize in oncology quiz at International Acute Lymphoblastic Leukaemia Conference

Chennai, India

2014

European Society of Medical Oncology (ESMO) Travel Award for Preceptorship on Immuno-oncology

Barcelona, Spain

 

 

 

PROFESSIONAL ACTIVITIES

Current Memberships in Professional Societies

American Society of Clinical Oncology (ASCO)

Canadian Society of Medical Oncology (CAMO)

European Society of Medical Oncology (ESMO)

Indian Society of Medical and Paediatric Oncology (ISMPO)

Multinational Association for Supportive Care in Cancer (MASCC)



Invited Journal Reviews

Journal of Global Oncology

PLoS One

British Medical Journal Case Reports

Indian Journal of Medical and Paediatric Oncology

National Medical Journal of India

RESEARCH PROJECTS

 

 

Ongoing Research Projects

A. Investigator-initiated

1. Randomized double-blind placebo-controlled trial of topical 1% diclofenac in prevention of capecitabine induced hand foot syndrome

2. Assessment of serum tumor marker response in patients receiving neoadjuvant chemotherapy in triple negative breast cancer

3. Assessment of symptom burden in cancer patients through an innovative mobile-based patient-reported outcomes system in India

Industry-sponsored (PI at site)

1. A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281).

2. A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

3. SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease



Completed

Year

Project

Role

 

2019

A multicenter phase 4, open-label, single-arm, safety

and efficacy study of enzalutamide in indian patients

With progressive metastatic castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy principal investigator.

 

Principal Investigator

for site

2017

Immunohistochemical expression of sirtuin-1 in osteosarcoma and correlation with survival outcomes.

Principal Investigator

 

2017

A prospective, multicenter, randomized, double-blind,

Parallel group study to compare the efficacy and

Safety of GBR 200 (similar biologic of trastuzumab)

Versus innovator trastuzumab, both when given in

Combination with paclitaxel in patients diagnosed with

Her2 positive metastatic breast cancer.

 

Co-Investigator

2017

A multicenter, open-label phase 2b study of selinexor (kpt-330) in patients with relapsed/refractory DLBCLwho have no therapeutic options of demonstrated clinical benefit.

Co-Investigator

2016

Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.

Co-Investigator

2015

Metronomic chemotherapy vs best supportive care inprogressive pediatric solid malignant tumors: a randomized clinical trial.

 

Research Staff

Shikha Jain (Junior Research Fellow)

Sneha Gund (Study Coordinator)

Akansha Dhakolia (Study Nurse)

Co-Investigator

 

 

INVITED ADRESSES



Year

Conference/Event

Topic

City, Country

2021

Best of SABCS New Delhi, India

CDK4/6 inhibitors in adjuvant setting in patients with breast cancer

Delhi, India

2020

Year in Review- Breast Cancer

Newer therapies in HER2 positive breast cancer

Mumbai, India

2018

Association of Breast Surgeons of India annual conference

Optimizing adjuvant treatment in early breast cancer patients

 

Delhi, India

2018

International Precision Oncology & Breast Cancer Conference

Role of comprehensive genomic sequencing in metastatic breast cancer

Jaipur, India

2018

Best of San Antonio Breast Cancer Symposium

Developments in metastatic hormone positive breast cancer in 2017

Delhi, India

2018

Treating Breast Cancer with Precision

Optimizing neoadjuvant chemotherapy in HER2 positive breast cancer

Chennai, India

2018

Updates in Breast Cancer by National Cancer Institute

Contemporary management of early triple negative breast cancer: Medical Oncologist’s perspective

Delhi, India

2018

Year in Review: Genitourinary Cancers

Sequencing of treatment in metastatic prostate cancer

Kolkata, India

2017

Updates in Gynaecological Cancers by National Cancer Institute

Role of bevacizumab in cervical cancer

Delhi, India

2017

Indian Gastrointestinal Oncology Meet

Advances in treatment of metastatic colon cancer

Mumbai, India

2017

Advances in Haematology

Stopping Imatinib in CML: Is this the right time?

Delhi, India

2017

36th ICON conference

Immunotherapy in renal cell cancer: A new era

Lucknow, India



PUBLICATIONS AND PRESENTATIONS

PubMed Indexed Publications

  • Sharma A, Sahoo RK, Batra A. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021 Nov 11;385(20):1919. doi: 10.1056/NEJMc2115204. PMID: 34758261.

  • Blomstrand H, Batra A, Cheung WY, Elander NO. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World J Clin Oncol. 2021 Sep 24;12(9):787-799. doi: 10.5306/wjco.v12.i9.787. PMID: 34631442; PMCID: PMC8479347.

  • Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhoriwal S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Ann Surg Oncol. 2021 Oct 2:1–10. doi: 10.1245/s10434-021-10870-w. Epub ahead of print. PMID: 34601666; PMCID: PMC8487333.

  • Batra A, Yusuf D, Hurry M, Walton RN, Devost N, Farrer C, Cheung WY. A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer. Am J Clin Oncol (e-pub ahead of print 11 August 2021; doi:10.1097/COC.0000000000000857)

  • Batra A, Tang PA, Cheung WY. Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. Am J Clin Oncol (e-pub ahead of print 9 August 2021; doi:10.1097/COC.0000000000000856).

  • Gupta N, Gupta A, Sarma R, Batra A, Madan K. Video laryngoscopy vs. direct laryngoscopy for nasotracheal intubation in oro-maxillofacial surgery: a systematic review and meta-analysis of randomized controlled trials. Korean J Anesthesiol (e-pub ahead of print 9 August 2021; doi:10.4097/kja.21234).

  • Batra A, Kong S, Cheung WY. Associations of Socioeconomic Status and Rurality With New-Onset Cardiovascular Disease in Cancer Survivors: A Population-Based Analysis. JCO Oncol Pract. 2021 Jul 9:OP2001053. doi: 10.1200/OP.20.01053. Epub ahead of print. PMID: 34242068.

  • Amaro CP, Batra A, Lupichuk S. First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta. Current Oncology 2021; 28: 2270–2280. [DOI: 10.3390/curroncol28030209]

  • Batra A, Nixon NA, Roldan-Urgoiti G, Hannouf MB, Abedin T, Hugh J, King K, Bigras G, Steed T, Lupichuk S. Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer. Cancer Treat Res Commun 2021; 28: 100401. [PMID: 34091374 DOI: 10.1016/j.ctarc.2021.100401]

  • Batra A, Yang L, Boyne DJ, Harper A, Cuthbert CA, Cheung WY. Symptom burden in patients with common cancers near end-of-life and its associations with clinical characteristics: a real-world study. Support Care Cancer 2021; 29: 3299–3309. [PMID: 33104922 DOI: 10.1007/s00520-020-05827-w]

  • Singh TP, Sharma A, Sharma A, Bakhshi S, Patel C, Pandey AK, Dhamija E, Batra A, Kumar R. Utility of 18F-FDG-PET/CT in management and prognostication of treatment naïve late-stage soft tissue sarcomas. Nucl Med Commun 2021; 42: 818–825. [PMID: 33741856 DOI: 10.1097/MNM.0000000000001401]

  • Batra A, Rigo R, Hannouf MB, Cheung WY. Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 2021; 20: e75–e81. [PMID: 33268287 DOI: 10.1016/j.clcc.2020.09.006]

  • Yadav S, Mathew R, Sahu AK, Jamshed N, Mohindra R, Aggarwal P, Batra A, Halder D, Brunda RL. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department. J Emerg Med 2021; 60: 641–647. [PMID: 33518374 DOI: 10.1016/j.jemermed.2020.12.010]

  • Batra A, Cheung WY. Role of real-world evidence in informing cancer care: lessons from colorectal cancer. Curr Oncol 2019; 26: S53–S56. [PMID: 31819710 DOI: 10.3747/co.26.5625]

  • Patel A, Gupta VG, Biswas B, Ganguly S, Das CK, Batra A, Bhethanabhotla S. Reply to D. O’Reilly et al. JCO Glob Oncol 2021; 7: 648. [PMID: 33956500 DOI: 10.1200/GO.21.00077]

  • Hannouf M, Batra A, Lupichuk S. Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008-2012. Curr Oncol 2021; 28: 1137–1142. [PMID: 33806441 DOI: 10.3390/curroncol28020109]

  • Boyne DJ, Cheung WY, Hilsden RJ, Sajobi TT, Batra A, Friedenreich CM, Brenner DR. Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer. JAMA Netw Open 2021; 4: e213587. [PMID: 33783516 DOI: 10.1001/jamanetworkopen.2021.3587]

  • Arora S, Kumar A, Batra A. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Early Triple-Negative Breast Cancer. JAMA Oncol 2021; 7: 460–461. [PMID: 33410889 DOI: 10.1001/jamaoncol.2020.7157]

  • Batra A, Yang L, Boyne DJ, Harper A, Cheung WY, Cuthbert CA. Associations between baseline symptom burden as assessed by patient-reported outcomes and overall survival of patients with metastatic cancer. Support Care Cancer 2021; 29: 1423–1431. [PMID: 32676854 DOI: 10.1007/s00520-020-05623-6]

  • Batra A, McKinnon G, Billawala A, Sheka D, Kong S, Cheung WY. Factors associated with the initiation of chemotherapy within 90 days of death in metastatic colorectal cancer patients: a population-based study. Support Care Cancer 2021; 29: 1535–1542. [PMID: 32725376 DOI: 10.1007/s00520-020-05655-y]

  • Batra A, Kumar A. HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic? Breast 2021; 55: 136. [PMID: 33328129 DOI: 10.1016/j.breast.2020.11.017]

  • Singh N, Batra A, Yang L, Boyne DJ, Harper A, Ghatage P, Cuthbert CA, Cheung WY. Patient-Reported Symptom Burden Near the End of Life in Patients With Gynaecologic Cancers. J Obstet Gynaecol Can 2021; 43: 26–33. [PMID: 32967796 DOI: 10.1016/j.jogc.2020.06.017]

  • Patel A, Gupta VG, Biswas B, Das CK, Batra A, Ganguly S, Bhethanabhotla S. Revisiting Fulvestrant Dosing in Uncertain Economic Times. JCO Glob Oncol 2021; 7: 1–3. [PMID: 33405958 DOI: 10.1200/GO.20.00362]

  • Batra A. Platelet Normalized Serum Vascular Endothelial Growth Factor Levels in Progressive Pediatric Solid Malignancies. Indian Pediatr 2020; 57: 1188.

  • Singh N, Al-Ruwaisan M, Batra A, Itani D, Ghatage P. Factors Affecting Overall Survival in Premenopausal Women With Uterine Leiomyosarcoma: A Retrospective Analysis With Long-Term Follow-Up. J Obstet Gynaecol Can 2020; 42: 1483–1488. [PMID: 32900677 DOI: 10.1016/j.jogc.2020.05.016]

  • Batra A, Kong S, Cheung WY. Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials. Clin Colorectal Cancer 2020; 19: e226–e234. [PMID: 32636076 DOI: 10.1016/j.clcc.2020.05.005]

  • Batra A, Kong S, Cheung WY. Eligibility of real-world patients with metastatic breast cancer for clinical trials. Breast 2020; 54: 171–178. [PMID: 33120082 DOI: 10.1016/j.breast.2020.10.005]

  • Batra A, Hannouf MB, Alsafar N, Lupichuk S. Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study. Breast 2020; 54: 1–7. [PMID: 32861882 DOI: 10.1016/j.breast.2020.08.002]

  • Batra A, Sheka D, Kong S, Cheung WY. Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer. BMC Cancer 2020; 20: 1004. [PMID: 33059611 DOI: 10.1186/s12885-020-07487-9]

  • Vanidassane I, Dhamija E, Naik SS, Batra A. An unusual durable response with palbociclib plus letrozole in hormone receptor positive metastatic breast cancer after multiple lines of therapy. Indian J Cancer 2020; 57: 348–350. [PMID: 32769294 DOI: 10.4103/ijc.IJC_66_19]

  • Ding PQ, Batra A, Xu Y, McKinnon GP, Cheung WY. Obesity and Its Impact on Outcomes in Patients With Stage III Colon Cancer Receiving Adjuvant Chemotherapy. Clin Colorectal Cancer 2020; 19: 209–218. [PMID: 32291245 DOI: 10.1016/j.clcc.2020.02.010]

  • Bosma NA, Tilley D, Batra A, Cheung WY. Characterizing Urban-Rural Differences in Colon Cancer Outcomes: A Population-based Analysis Based on Travel Distance to Cancer Center. Am J Clin Oncol 2020; 43: 531–535. [PMID: 32324599 DOI: 10.1097/COC.0000000000000703]

  • Batra A, Rigo R, Sheka D, Cheung WY. Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. World J Gastrointest Oncol 2020; 12: 604–618. [PMID: 32699576 DOI: 10.4251/wjgo.v12.i6.604]

  • Vanidassane I, Naik RD, Sharma V, Khurana S, Batra A. Adjuvant trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: Take-home points from the KATHERINE trial. Natl Med J India 2020; 33: 158–159. [PMID: 33904420 DOI: 10.4103/0970-258X.314006]

  • Patel A, Tannock IF, Srivastava P, Biswas B, Gupta VG, Batra A, Bhethanabhotla S, Pramanik R, Mahindru S, Tilak T, Das CK, Mehta P. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol 2020; 6: 382–386. [PMID: 32125899 DOI: 10.1200/JGO.19.00341]

  • Baa AK, Naik RD, Vanidassane I, Arora S, Shamim SA, Mallick S, Batra A. Unusual Gastric Metastasis in Triple-Negative (Estrogen Receptor/Progesterone Receptor/HER2neu Negative) GATA-Binding Protein 3-Positive Breast Cancer. Indian J Nucl Med 2020; 35: 82–83. [PMID: 31949382 DOI: 10.4103/ijnm.IJNM_156_19]

  • Mian A, Kumari K, Kaushal S, Fazal F, Kodan P, Batra A, Kumar P, Baitha U, Jorwal P, Soneja M, Sharma MC, Biswas A. Fatal familial hemophagocytic lymphohistiocytosis with perforin gene (PRF1) mutation and EBV-associated T-cell lymphoproliferative disorder of the thyroid. Autops Case Rep 2019; 9: e2019101. [PMID: 31440481 DOI: 10.4322/acr.2019.101]

  • Mittal A, Batra A. Adjuvant chemotherapy in early breast cancer: Are we over-treating patients? Natl Med J India 2019; 32: 230–231. [PMID: 32769244 DOI: 10.4103/0970-258X.291305]

  • Batra A, Patel A, Gupta VG, Mehta P, Tvsvgk T, Biswas B, Pramanik R, Das CK, Srivastava P. Oncotype DX: Where Does It Stand in India? J Glob Oncol 2019; 5: 1–2. [PMID: 31310569 DOI: 10.1200/JGO.19.00151]

  • Vanidassane I, Sharma V, Ramteke P, Yadav MK, Batra A. Primary Yolk Sac Tumor of the Liver in an Adult Man. ACG Case Rep J 2019; 6: e00050. [PMID: 31616734 DOI: 10.14309/crj.0000000000000050]

  • Naik RD, Batra A, Gupta VG. Palbociclib and Fulvestrant in Breast Cancer. N Engl J Med 2019; 380: 796. [PMID: 30786199 DOI: 10.1056/NEJMc1816595]

  • Patekar M, Adhikari N, Biswas A, Raina V, Kumar L, Mohanti BK, Gogia A, Sharma A, Batra A, Bakhshi S, Garg A, Thulkar S, Sharma MC, Vishnubhatla S, Baghmar S, Sahoo RK. Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences. J Glob Oncol 2019; 5: 1–9. [PMID: 30811305 DOI: 10.1200/JGO.18.00124]

  • Vanidassane I, Mittal A, Kumar C, Tanwar P, Sahoo RK, Batra A. Skin metastasis: a rare presentation in testicular germ cell tumour. BMJ Case Rep 2018; 2018. [PMID: 30249738 DOI: 10.1136/bcr-2018-226385]

  • Biswas B, Ganguly S, Ghosh J, Batra A. Cisplatin-induced hearing loss in children with cancer. Natl Med J India 2017; 30: 327–328. [PMID: 30117444 DOI: 10.4103/0970-258X.239073]

  • Pramanik R, Agarwala S, Gupta YK, Thulkar S, Vishnubhatla S, Batra A, Dhawan D, Bakhshi S. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial. JAMA Oncol 2017; 3: 1222–1227. [PMID: 28384657 DOI: 10.1001/jamaoncol.2017.0324]

  • Srivastava R, Batra A, Dhawan D, Bakhshi S. Association of energy intake and expenditure with obesity: A cross-sectional study of 150 pediatric patients following treatment for leukemia. Pediatr Hematol Oncol 2017; 34: 29–35. [PMID: 28287332 DOI: 10.1080/08880018.2016.1272025]

  • Batra A, Kashyap S, Singh L, Bakhshi S. Expression of FOXO3a and Correlation With Histopathologic Features in Retinoblastoma. Appl Immunohistochem Mol Morphol 2017; 25: 95–99. [PMID: 26574636 DOI: 10.1097/PAI.0000000000000278]

  • Biswas B, Rastogi S, Batra A, Ganguly S. Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer. Natl Med J India 2016; 29: 219–220.

  • Dabas A, Batra A, Khadgawat R, Jyotsna VP, Bakhshi S. Growth and Endocrinal Abnormalities in Pediatric Langerhans Cell Histiocytosis. Indian J Pediatr 2016; 83: 657–660. [PMID: 26988579 DOI: 10.1007/s12098-016-2053-y]

  • Batra A, Kain R, Kumari M, Paul R, Dhawan D, Bakhshi S. Parents’ Perspective of Quality of Life of Retinoblastoma Survivors. Pediatr Blood Cancer 2016; 63: 1287–1289. [PMID: 27038275 DOI: 10.1002/pbc.25982]

  • Batra A, Kumari M, Paul R, Patekar M, Dhawan D, Bakhshi S. Quality of Life Assessment in Retinoblastoma: A Cross-Sectional Study of 122 Survivors from India. Pediatr Blood Cancer 2016; 63: 313–317. [PMID: 26488435 DOI: 10.1002/pbc.25781]

  • Batra A, Kashyap S, Singh L, Bakhshi S. Sirtuin1 Expression and Correlation with Histopathological Features in Retinoblastoma. Ocul Oncol Pathol 2015; 2: 86–90. [PMID: 27172132 DOI: 10.1159/000439594]

  • Nataraj V, Batra A, Rastogi S, Khan SA, Sharma MC, Vishnubhatla S, Bakhshi S. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. J Surg Oncol 2015; 112: 662–668. [PMID: 26381138 DOI: 10.1002/jso.24045]

  • Batra A, Thakar A, Bakhshi S. Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: A cross-sectional study of 116 patients. Pediatr Blood Cancer 2015; 62: 2060. [PMID: 26053139 DOI: 10.1002/pbc.25618]

  • Bakhshi S, Batra A, Biswas B, Dhawan D, Paul R, Sreenivas V. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2015; 23: 3229–3237. [PMID: 25851802 DOI: 10.1007/s00520-015-2714-9]

  • Batra A, Bakhshi S. Aprepitant for paediatric chemotherapy-induced nausea and vomiting. Lancet Oncol 2015; 16: e259-260. [PMID: 26065606 DOI: 10.1016/S1470-2045(15)70244-5]

  • Singh N, Tripathi R, Mala Y, Batra A. Diagnostic Dilemma in Cornual Pregnancy- 3D Ultrasonography may Aid!! J Clin Diagn Res 2015; 9: QD12-13. [PMID: 25738045 DOI: 10.7860/JCDR/2015/6775.5484]

  • Kumar L, Iqbal N, Mookerjee A, Verma RK, Sharma OD, Batra A, Pramanik R, Gupta R. Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med 2014; 3: 939–946. [PMID: 24777883 DOI: 10.1002/cam4.257]

  • Batra A, Pushker N, Venkatesh P, Arora T, Tewari R, Bakhshi S. Long-term visual outcomes in intraocular retinoblastoma with eye preservation. Clin Transl Oncol 2016; 18: 1034–1038. [PMID: 26781471 DOI: 10.1007/s12094-016-1482-4]

  • Batra A, Patekar M, Bakhshi S. Short stature in retinoblastoma survivors: a cross-sectional study of 138 patients. Clin Transl Oncol 2016; 18: 381–384. [PMID: 26286069 DOI: 10.1007/s12094-015-1380-1]

  • Singh N, Tripathi R, Tyagi S, Batra A. Antepartum fetal bladder rupture leading to urinary ascitis: attempt to rescue by placement of peritoneo-amniotic shunt. BMJ Case Rep 2013; 2013. [PMID: 23946514 DOI: 10.1136/bcr-2013-200021]

  • Singh N, Tripathi R, Mala YM, Dixit R, Tyagi S, Batra A. Comparison of scar thickness measurements using trans-vaginal sonography and MRI in cases of pregnancy with previous caesarean section. Do they correlate with actual scar thickness? Journal of Obstetrics and Gynaecology 2013; 33: 810–813. [PMID: 24219719 DOI: 10.3109/01443615.2013.823926]

  • Soneja M, Batra A, Vikram NK, Ahuja A, Mohan A, Sood R. Actinomycosis and nocardiosis co-infection in chronic granulomatous disease. J Assoc Physicians India 2012; 60: 66–68.

  • Gupta S, Singh S, Sarkar S, Batra A. Development and validation of the ethical challenges in clinical situations-questionnaire (ECCS-Q) by involving health-care providers from a tertiary care health setting. Clinical Ethics. April 2021. doi:10.1177/14777509211011427

  • Dabkara D, Ganguly S, Ghosh J, Patel A, Batra A, Das CK, et al. How We Treat Genitourinary Cancers During COVID-19 Pandemic? 1 2020;5:147–52. https://doi.org/10.31557/apjcc.2020.5.S1.147-152.

  • Ghosh J, Ganguly S, Biswas B, Dabkara D, Srivastava P, Patel A, et al. Systemic treatment of gastroesophageal cancer during SARS-CoV2. Indian Journal of Medical and Paediatric Oncology 2020;41:141. https://doi.org/10.4103/ijmpo.ijmpo_118_20.

  • Bhethanabhotla S, Pramanik R, Srivastava P, Mehta P, Patel A, Biswas B, et al. Colorectal cancer chemotherapy during COVID-19 pandemic. Indian Journal of Medical and Paediatric Oncology 2020;41:156. https://doi.org/10.4103/ijmpo.ijmpo_149_20.

  • Pramanik R, Srivastava P, Sharma A, Mehta P, Patel A, Bhethanbhotla S, et al. Management of head-and-neck cancer during COVID-19 crisis: A medical oncology perspective. Indian Journal of Medical and Paediatric Oncology 2020;41:153. https://doi.org/10.4103/ijmpo.ijmpo_134_20.

  • Mahindru S, Das CK, Patel A, Mehta P, Biswas B, Batra A, et al. Cancer surgery in challenging time of COVID-19 pandemic – A pragmatic approach. Indian Journal of Medical and Paediatric Oncology 2020;41:144. https://doi.org/10.4103/ijmpo.ijmpo_121_20.

  • Das CK, Mahindru S, Patel A, Batra A, Biswas B, Mehta P, et al. How I treat epithelial ovarian cancer during COVID-19 pandemic. Indian Journal of Medical and Paediatric Oncology 2020;41:138. https://doi.org/10.4103/ijmpo.ijmpo_112_20.

  • Batra A, Mehta P, Patel A, Bhethanabhotla S, Biswas B, Pramanik R, et al. Breast cancer treatment during the COVID-19 pandemic. Indian Journal of Medical and Paediatric Oncology 2020;41:135. https://doi.org/10.4103/ijmpo.ijmpo_111_20.

  • Patel A, Batra A, Mehta P, Sharma A, Sirohi B, Biswas B, et al. Gallbladder cancer: Adjuvant and palliative treatment during Covid-19 pandemic in India. Indian Journal of Medical and Paediatric Oncology 2020;41:132. https://doi.org/10.4103/ijmpo.ijmpo_110_20.

  • Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, et al. How we treat lung cancer during SARS-Cov-2 (COVID-19) pandemic in India? Indian Journal of Medical and Paediatric Oncology 2020;41:149. https://doi.org/10.4103/ijmpo.ijmpo_122_20.

  • Mehta P, Parikh P, Aggarwal S, Batra A, Patel A, Kulkarni P, et al. Has India met this enemy before? From an eternal optimist’s perspective: SARS-CoV-2. IJMS 2020;72:8–12. https://doi.org/10.25259/IJMS_30_2020.

  • Parikh P, Mehta P, Bansal S, Aggarwal S, Patel A, Batra A, et al. Protecting health-care professionals and workers (other than COVID-19 management facilities) from contamination during COVID-19 pandemic (March 26, 2020 – India). IJMS 2020;72:3–4. https://doi.org/10.25259/IJMS_28_2020.

  • Sharma A, Mittal A, Barwad A, Mridha AR, Venkatesan S, Sahoo RK, et al. Recurrent germ cell tumour presenting as fractured neck of the femur: Journal of Clinical Urology 2019. https://doi.org/10.1177/2051415819841964.

  • Pushpam D, Raj A, Batra A, Bakhshi S. Occam’s razor versus Hickam’s dictum: An unusual cause of acute renal failure in pediatric solid malignancy. Indian Journal of Medical and Paediatric Oncology 2019;40:445. https://doi.org/10.4103/ijmpo.ijmpo_54_18.

  • Patel A, Tilak TV, Gupta VG, Batra A, Mehta P, Parikh P, et al. Dynamics of sequencing of cyclin-dependent kinase inhibitors and cost expenditure analysis in the management of metastatic hormone-receptor positive, human epidermal growth factor 2-negative advanced breast cancer. Indian Journal of Medical and Paediatric Oncology 2019;40:311. https://doi.org/10.4103/ijmpo.ijmpo_111_19.

  • Mehta P, Batra A, Patel A. Commentary on oncotype Dx. Indian Journal of Medical and Paediatric Oncology 2019;40:434. https://doi.org/10.4103/ijmpo.ijmpo_226_19.

  • Pramanik R, Kancharla H, Bakhshi S, Sharma A, Gogia A, Malik P, Sahoo RK, Batra A, Thulkar S, Kumar L. Engraftment Syndrome: A Retrospective Analysis of the Experience at a Tertiary Care Institute. Clinical Hematology International 2019; 1: 114–119. [DOI: 10.2991/chi.d.190504.001]



ABSTRACTS

  • Batra A, Kong S, Rigo R, Cheung WY. Impact of preexisting cardiovascular disease (CVD) on treatments and outcomes of patients with breast or lung cancer. JCO. 2020;38(15_suppl):12063-12063. doi:10.1200/JCO.2020.38.15_suppl.12063

  • Batra A, Cuthbert CA, Harper A, et al. Impact of baseline symptom burden as assessed by patient-reported outcomes (PROs) on overall survival (OS) of patients with metastatic cancer. JCO. 2020;38(15_suppl):12020-12020. doi:10.1200/JCO.2020.38.15_suppl.12020

  • Batra A, Kong S, Rigo R, Cheung W. 150P Eligibility of real-world patients with metastatic breast cancer in clinical trials. Annals of Oncology. 2020;31:S70. doi:10.1016/j.annonc.2020.03.250

  • Batra A, Cuthbert C, Rigo R, et al. 187P Patient-reported outcomes near end-of-life in patients with breast cancer. Annals of Oncology. 2020;31:S84. doi:10.1016/j.annonc.2020.03.126

  • Rigo R, Koczka K, Batra A, Cheung WY, Monzon JG, Cheng T. Adjuvant systemic therapies for melanoma in Alberta: An early descriptive analysis of population characteristics and treatment outcomes. JCO. 2020;38(15_suppl):e22013-e22013. doi:10.1200/JCO.2020.38.15_suppl.e22013

  • Peng J, Batra A, Cheung WY. Referral-to-treatment attrition and its impact on outcomes of patients with advanced gastroesophageal cancers. JCO. 2020;38(15_suppl):e16504-e16504. doi:10.1200/JCO.2020.38.15_suppl.e16504

  • Cheung WY, Rigo R, Batra A. Use of Twitter among cancer clinicians and researchers and the associations with scientific impact of its users and followers. JCO. 2020;38(15_suppl):e14101-e14101. doi:10.1200/JCO.2020.38.15_suppl.e14101

  • Batra A, Kong S, Cheung WY. Eligibility of real-world patients with stage II/III colorectal cancer (CRC) in adjuvant chemotherapy (AC) trials. JCO 2020;38:50–50 [DOI: 10.1200/JCO.2020.38.4_suppl.50]

  • Batra A, Cheung WY, Tang PA. Real-world eligibility of advanced pancreatic (APC) patients for maintenance olaparib. JCO 2020;38:653–653 [DOI: 10.1200/JCO.2020.38.4_suppl.653]

  • Mayank Singh, Atul Batra, Sameer Bakhshi, Matthew Summers. Validation of Ubiquitin specific peptidases 37 as a prognostic and diagnostic marker in osteosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1256.

  • Batra A, Dhawan D, Paul R, Kumari M, Bakhshi S.Improvement in Compliance of Patients with Non-Metastatic Retinoblastoma with Low-Cost Prospective Database and Patient Tracking System: A Study from Tertiary Care Centre in India. Pediatric Blood & Cancer. Volume 64, Issue S3, November 2017. Version of Record online : 1 Sep 2017, doi: 10.1002/pbc.26772

  • Biswas B, Jha A, Batra A, Sengupta M, Bakhshi S. Pretreatment neutrophilto lynphocyte ratio in ewing sarcoma family of tumors: An analysis of 570 patients. JCO 2017;35:e22504–e22504 [DOI: 10.1200/JCO.2017.35.15_suppl.e22504]

  • Pramanik R, Batra A, Agarwala S, Gupta YK, Thulkar S, Vishnubhatla S, Dhawan D, Bakhshi S. Progressive Paediatric Solid Tumours other than Bone-Sarcomas Benefit from Metronomic Chemotherapy: A Subgroup Analysis from a Double Blind Placebo Controlled Randomized Study. SIOP 2016 Scientific Programme+Index. Pediatr Blood Cancer, 63: S5–S321.doi:10.1002/pbc.26233.

  • Batra A, Bakhshi S, Pushker N.Prognostic Factors in Metastatic Retinoblastoma: A Study of 70 Metastatic Retinoblastoma Patients Treated at a Single Centre in India. SIOP 2016 Scientific Programme+Index. Pediatr Blood Cancer, 63: S5–S321. doi:10.1002/pbc.26233.

  • Batra A, Kashyap S, Pushker N, Meel R, Bakhshi S. Retinoblastoma in Children Older Than 6 Years: A Single Centre Study of 58 Patients from India. SIOP 2016 Scientific Programme+Index. Pediatr Blood Cancer, 63: S5–S321. doi:10.1002/pbc.26233.

  • Batra A, Pushker N, Venkatesh N, Arora T, Tewari R, Bakhshi S. Correlation of Quality of Life and Visual Acuity in Survivors of Bilateral Retinoblastoma Managed with Enucleation of One Eye and Salvage of Other Eye. Support Care Cancer (2016) 24(Suppl 1): 1. https://doi.org/10.1007/s00520-016-3209-z.

  • Pramanik R, Bakhshi S, Agarwala S, Gupta YK, Thulkar S, Vishnubhatla S, Batra A, Dhawan D. Metronomic therapy versus best supportive care in progressive pediatric solid malignancies: A double blind placebo controlled randomized study. JCO 2016;34:10520–10520 [DOI: 10.1200/JCO.2016.34.15_suppl.10520]

  • Batra A, Kumari M, Paul R, Dhawan D , Bakhshi S. Quality of life in retinoblastoma: Quality of life assessment in retinoblastoma: A cross-sectional study of 122 survivors.10.1200/jco.2015.33.15_suppl.10068 Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 10068-10068.

  • Batra A, Pushker N, Venkatesh N, Bakhshi S. Visual outcomes and ocular coherence tomography in patients with intraocular retinoblastoma with eye preservation. Annals of Oncology, Volume 26, Issue suppl_9, 1 December 2015, Pages ix156, https://doi.org/10.1093/annonc/mdv535.02.

  • Bakhshi S, Batra A, Kumari M, Paul R, Patekar M, Dhawan D. Parents’ Perspective Of Quality Of Life In Retinoblastoma Survivors: A Cross-Sectional Study Of 122 Patients. SIOP 2015 Scientific Programme + Index. Pediatr Blood Cancer, 62: S143–S418. doi:10.1002/pbc.25715.

  • Batra A, Kashyap S, Singh L, Bakhshi S. Cytoplasmic Expression of Foxo3a in Retinoblastoma Predicts High Risk Histopathological Features. A Cross-Sectional Study Of 122 Patients. SIOP 2015 Scientific Programme + Index. Pediatr Blood Cancer, 62: S143–S418. doi:10.1002/pbc.25715.

  • Batra A, Kashyap S, Singh L, Bakhshi S. Sirtuin1 Expression and Correlation with Histopathological Features In Retinoblastoma. SIOP 2015 Scientific Programme + Index. Pediatr Blood Cancer, 62: S143–S418. doi:10.1002/pbc.25715.

  • Batra A, Thakar A, Patekar M, Bakhshi S. Long-term non-visual outcomes in retinoblastoma survivors SIOP 2015 Scientific Programme + Index. Pediatr Blood Cancer, 62: S143–S418. doi:10.1002/pbc.25715.

  • Batra A, Shrivastava R, Tyagi A , Dhawan D, Ramakrishnan L, Bakhshi S. An Insight Into The Biomarkers Of Obesity In Survivors Of Acute Leukemia. 46th Congress of the International Society of Paediatric Oncology (SIOP) 2014. Pediatr Blood Cancer, 61: S105–S433. doi:10.1002/pbc.25314.

  • Bakhshi S, Batra A, Biswas B, Dhawan D, Paul R, Sreenivas V. Aprepitant As An Add-On Therapy In Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double Blind, Placebo-Controlled Trial. 46th Congress of the International Society of Paediatric Oncology (SIOP) 2014. Pediatr Blood Cancer, 61: S105–S433. doi:10.1002/pbc.25314.

     

     

Presentations

Year

Conference/Venue

Abstract(s)

Presentation

(Award)

 

2020

ESMO Annual Congress

 

i. Association of pre-existing cardiovascular disease (CVD) in older patients with breast cancer with treatment and survival outcomes

 

ii. Determinants of new onset cardiovascular disease (CVD) in cancer patients

 

Mini-oral

 

 

 

E-Poster

 

2020

ESMO World Congress on Gastrointestinal cancers

 

Barcelona, Spain

 

 

  1. Impact of baseline symptom burden as assessed by patient-reported outcomes (PROs) on overall survival (OS) of patients with metastatic gastrointestinal (GI) cancer

 

  1. Patient-reported outcomes in patients with gastric and esophageal cancers near end-of-life

 

 

Poster discussion

(Young Investigator Award)

 

 

 

Poster

 

2020

ASCO Annual meeting 2020, Chicago, USA

 

 

  1. Impact of preexisting cardiovascular disease (CVD) on treatments and outcomes of patients with breast or lung cancer.

 

  1. Impact of baseline symptom burden as assessed by patient-reported outcomes (PROs) on overall survival (OS) of patients with metastatic cancer.

 

 

Poster

(ASCO Merit Award)

 

 

Poster discussion

 

2020

ESMO Breast 2020, Berlin, Germany

 

 

  1. Patient-reported outcomes near end-of-life in patients with breast cancer 

 

  1. Eligibility of real-world patients with metastatic breast cancer in clinical trials 

 

Poster

 

Poster

(Merit Award)

 

 

2020

Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting, Seville, Spain

(Accepted, to be presented)

  1. Impact of pre-existing cardiovascular disease on treatment patterns and outcomes in patients with lung cancer

 

  1. Physical and psychological symptom burden near end of life in patients with lung cancer using patient-reported outcomes

 

Eposter

 

 

 

Eposter

 

2020

Canadian Association of Medical Oncology (CAMO) Annual Meeting, Toronto, Canada

(Accepted, to be presented)

Eligibility of real-world patients with stage II/III colorectal cancer in adjuvant chemotherapy trials

 

Oral

 

2020

American Society of Clinical Oncology (ASCO) GI Symposium, San Francisco, USA

  1. Eligibility of real-world patients with stage II/III colorectal cancer in adjuvant chemotherapy trials.

 

  1. Real-world eligibility of advanced pancreatic patients for maintenance olaparib

Poster

 

 

Poster

 

2017

International Society of Paediatric Oncology (SIOP) Annual Meeting, Washington DC, USA

Improvement in compliance of patients with non-metastatic retinoblastoma with low-cost prospective database and patient tracking system: a study from tertiary care centre in India.

Oral,

Young Investigator Award

 

2016

SIOP Annual Meeting, Dublin, Ireland

  1. Prognostic factors in metastatic retinoblastoma: a study of 70 metastatic retinoblastoma patients treated at a single centre in India

 

  1. Retinoblastoma in children older than 6 years: a single centre study of 58 patients from India

E-poster

 

 

 

 

 

2016

MASCC, Adelaide, Australia

Correlation of quality of life and visual acuity in survivors of bilateral retinoblastoma managed with enucleation of one eye and salvage of other eye

Oral,

Travel Scholarship Award

 

2015

ASCO Annual Meeting, Chicago, USA

Quality of life assessment in retinoblastoma: a cross-sectional study of 122 survivors.

Poster,

ICMR Travel Award

 

2015

ESMO Asia, Singapore

Visual outcomes and ocular coherence tomography in patients with intraocular retinoblastoma with eye preservation.

Poster

ESMO Travel Award

 

2015

SIOP Annual Meeting, Capetown, South Africa

  1. Long-term non-visual outcomes in retinoblastoma survivors



  1. Expression of Foxo3a in Retinoblastoma Predicts High Risk Histopathological Features. A Cross-Sectional Study Of 122 Patients.



  1. Sirtuin1 Expression and Correlation with Histopathological Features In Retinoblastoma.

Oral

Young Investigator Award

E-poster

 

 

 

E-poster

 

2014

SIOP Annual Meeting, Toronto, Canada

An insight into the biomarkers of obesity in survivors of acute leukaemia.

Poster

 

 

 

 

 

 

 

 

 

 

 



 

 

 

Dr Lalit Kumar

Dr Lalit Kumar, MD; DM

Professor and Head

Department of Medical Oncology

All India Institute of Medical sciences

(Dr BRA Institute Rotary Cancer Hospital)

New Delhi 110029, India

E-Mail:   medoncoaiims This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 

Research Interests

  • Blood stem cell /Bone marrow transplantation
  • Hematological malignancies, (Multiple myeloma , chronic myeloid leukaemia, Infections)
  • Gynaecological malignancies: Role of neo-adjuvant Chemotherapy

 

Zo2 Framework Settings

Select one of sample color schemes

Google Font

Menu Font
Body Font
Heading Font

Body

Background Color
Text Color
Link Color
Background Image

Header Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image

Menu Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image

Main Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image

Inset Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image

Bottom Wrapper

Background Color
Modules Title
Text Color
Link Color
Background Image
Background Color
Modules Title
Text Color
Link Color
Background Image
 
Top of Page